Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin + trastuzumab + pertuzumab as neoadjuvant therapy for HER2-positive breast cancer
ChiCTR2600120346Phase 4Recruiting
- Sponsor
- The First Hospital of Jilin University
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of eribulin, trastuzumab and pertuzumab in breast cancer, sponsored by The First Hospital of Jilin University. Primary endpoints: Total Pathological Complete Response Rate, Breast Pathological Complete Response Rate and 3 more. Started Mar 2026; status: recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2600120346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600120346.